Lenvima®

Active substance lenvatinib
Holder     Eisai
Status closed
Indication in combination with pembrolizumab for the treatment of patients with advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation. 
Public documents Approbation
  Information for the patient
  Informed consent
Last update 02/09/2022

 

Last updated on 13/02/2024